Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBT Margin (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EBT Margin for 5 consecutive years, with 11746.15% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 1482077.0% year-over-year to 11746.15%, compared with a TTM value of 1092.36% through Dec 2025, down 1568322.0%, and an annual FY2025 reading of 1092.36%, up 3809327.0% over the prior year.
  • EBT Margin was 11746.15% for Q4 2025 at Aligos Therapeutics, down from 4248.45% in the prior quarter.
  • Across five years, EBT Margin topped out at 13868.49% in Q1 2025 and bottomed at 100884.21% in Q3 2024.
  • Average EBT Margin over 5 years is 6797.18%, with a median of 1135.19% recorded in 2023.
  • The sharpest move saw EBT Margin plummeted -10004800bps in 2024, then skyrocketed 9663576bps in 2025.
  • Year by year, EBT Margin stood at 10292.1% in 2021, then skyrocketed by 98bps to 157.02% in 2022, then tumbled by -366bps to 731.13% in 2023, then soared by 521bps to 3074.62% in 2024, then tumbled by -482bps to 11746.15% in 2025.
  • Business Quant data shows EBT Margin for ALGS at 11746.15% in Q4 2025, 4248.45% in Q3 2025, and 1624.66% in Q2 2025.